1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Alvarez-Garcia I and Miska EA: MicroRNA
functions in animal development and human disease. Development.
132:4653–4662. 2005. View Article : Google Scholar : PubMed/NCBI
|
4
|
Sassen S, Miska EA and Caldas C: MicroRNA:
Implications for cancer. Virchows Arch. 452:1–10. 2008. View Article : Google Scholar
|
5
|
Takasaki S: Roles of microRNAs in cancers
and development. Methods Mol Biol. 1218:375–413. 2015. View Article : Google Scholar
|
6
|
Hung CH, Chiu YC, Chen CH and Hu TH:
MicroRNAs in hepatocellular carcinoma: Carcinogenesis, progression,
and therapeutic target. Biomed Res Int. 2014:4864072014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Lim L, Balakrishnan A, Huskey N, Jones KD,
Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, et al:
MicroRNA-494 within an oncogenic microRNA megacluster regulates
G1/S transition in liver tumorigenesis through suppression of
mutated in colorectal cancer. Hepatology. 59:202–215. 2014.
View Article : Google Scholar :
|
8
|
Ohta K, Hoshino H, Wang J, Ono S, Iida Y,
Hata K, Huang SK, Colquhoun S and Hoon DS: MicroRNA-93 activates
c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by
directly inhibiting PTEN and CDKN1A. Oncotarget. 6:3211–3224. 2015.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Gao B, Gao K, Li L, Huang Z and Lin L:
miR-184 functions as an oncogenic regulator in hepatocellular
carcinoma (HCC). Biomed Pharmacother. 68:143–148. 2014. View Article : Google Scholar
|
10
|
Kim HS, Lee KS, Bae HJ, Eun JW, Shen Q,
Park SJ, Shin WC, Yang HD, Park M, Park WS, et al: MicroRNA-31
functions as a tumor suppressor by regulating cell cycle and
epithelial-mesenchymal transition regulatory proteins in liver
cancer. Oncotarget. 6:8089–8102. 2015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH,
Kim MG, Chang YG, Shen Q, Kim SJ, Park WS, et al: MicroRNA-29c
functions as a tumor suppressor by direct targeting oncogenic SIRT1
in hepatocellular carcinoma. Oncogene. 33:2557–2567. 2014.
View Article : Google Scholar
|
12
|
Zhang JP, Zeng C, Xu L, Gong J, Fang JH
and Zhuang SM: MicroRNA-148a suppresses the epithelial-mesenchymal
transition and metastasis of hepatoma cells by targeting Met/Snail
signaling. Oncogene. 33:4069–4076. 2014. View Article : Google Scholar
|
13
|
Liu LL, Lu SX, Li M, Li LZ, Fu J, Hu W,
Yang YZ, Luo RZ, Zhang CZ and Yun JP: FoxD3-regulated microRNA-137
suppresses tumour growth and metastasis in human hepatocellular
carcinoma by targeting AKT2. Oncotarget. 5:5113–5124. 2014.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Luo C, Tetteh PW, Merz PR, Dickes E,
Abukiwan A, Hotz-Wagenblatt A, Holland-Cunz S, Sinnberg T, Schittek
B, Schadendorf D, et al: miR-137 inhibits the invasion of melanoma
cells through downregulation of multiple oncogenic target genes. J
Invest Dermatol. 133:768–775. 2013. View Article : Google Scholar
|
15
|
Wright C, Turner JA, Calhoun VD and
Perrone-Bizzozero N: Potential impact of miR-137 and its targets in
schizophrenia. Front Genet. 4:582013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Chen Q, Chen X, Zhang M, Fan Q, Luo S and
Cao X: miR-137 is frequently down-regulated in gastric cancer and
is a negative regulator of Cdc42. Dig Dis Sci. 56:2009–2016. 2011.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Zhu X, Li Y, Shen H, Li H, Long L, Hui L
and Xu W: miR-137 inhibits the proliferation of lung cancer cells
by targeting Cdc42 and Cdk6. FEBS Lett. 587:73–81. 2013. View Article : Google Scholar
|
18
|
Liu M, Lang N, Qiu M, Xu F, Li Q, Tang Q,
Chen J, Chen X, Zhang S, Liu Z, et al: miR-137 targets Cdc42
expression, induces cell cycle G1 arrest and inhibits invasion in
colorectal cancer cells. Int J Cancer. 128:1269–1279. 2011.
View Article : Google Scholar
|
19
|
Arias-Romero LE and Chernoff J: Targeting
Cdc42 in cancer. Expert Opin Ther Targets. 17:1263–1273. 2013.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Stengel K and Zheng Y: Cdc42 in oncogenic
transformation, invasion, and tumorigenesis. Cell Signal.
23:1415–1423. 2011. View Article : Google Scholar : PubMed/NCBI
|
21
|
van Hengel J, D'Hooge P, Hooghe B, Wu X,
Libbrecht L, De Vos R, Quondamatteo F, Klempt M, Brakebusch C and
van Roy F: Continuous cell injury promotes hepatic tumori-genesis
in cdc42-deficient mouse liver. Gastroenterology. 134:781–792.
2008. View Article : Google Scholar : PubMed/NCBI
|
22
|
Zhang Y, Takahashi S, Tasaka A, Yoshima T,
Ochi H and Chayama K: Involvement of microRNA-224 in cell
proliferation, migration, invasion, and anti-apoptosis in
hepatocellular carcinoma. J Gastroenterol Hepatol. 28:565–575.
2013. View Article : Google Scholar
|
23
|
Wang R, Zhao N, Li S, Fang JH, Chen MX,
Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses
angio-genesis and metastasis of hepatocellular carcinoma by
inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology.
58:642–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
24
|
Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue
Q, Chen J, Gao DM and Bao WH: Establishment of cell clones with
different metastatic potential from the metastatic hepatocellular
carcinoma cell line MHCC97. World J Gastroenterol. 7:630–636.
2001.
|